Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
Type:
Grant
Filed:
January 31, 2008
Date of Patent:
November 12, 2013
Assignee:
Allergan, Inc.
Inventors:
Glenn T Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
Abstract: The present invention relates to a method for manufacturing an implant, in particular an intraluminal endoprosthesis, having a body containing metallic material, preferably iron. The following manufacturing method is provided for promotion of the anti-inflammatory effect of the implant: (i) providing the body of the implant; (ii) producing an at least partially closed pore structure in a portion of the structure of the implant body close to the surface; and (iii) incorporating NOX into the cavities of the pore structure. Also described is an implant manufactured in this manner.
Abstract: The invention is a method and kit for conducting a rapid toxicity test. Methods and kits according to the invention include an animal or plant species in diapause.
Type:
Grant
Filed:
January 27, 2006
Date of Patent:
November 5, 2013
Assignee:
The United States of America as Represented by the Secretary of the Army
Inventors:
Tommy R Shedd, Mark W Widder, Eugene Hull
Abstract: The present invention relates to the use of Ang-(1-7) and/or Ang-(1-7) receptor agonist and/or Ang (1-7) analogue in treating/restoring erectile dysfunction.
Type:
Grant
Filed:
January 24, 2008
Date of Patent:
November 5, 2013
Assignee:
Universidade Federal de Minas Garais-UFMG
Inventors:
Robson Augusto Souza dos Santos, Ruben Dario Sinisterra Millan, Frederic Jean Georges Frezard, Andrey Christian da Costa Goncalves, Rodrigo Araujo Fraga da Silva
Abstract: A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink.
Abstract: Pharmaceutical formulation in the form of compacts comprising A) an agglomerated excipient content composed of a1) 60-97% by weight of sugar or sugar alcohols, a2) 1-25% by weight of a disintegrant, selected from the group consisting of crospovidone, croscarmellose, sodium carboxymethylstarch and L-hydroxypropylcellulose, a3) 1-15% by weight of water-insoluble, film-forming polymers a4) 0-15% by weight of water-soluble polymers and a5) 0-15% by weight of further pharmaceutically customary excipients, the total of the components a1) to a5) being 100% by weight, B) at least one active ingredient, C) 0 to 10% by weight, based on the total amount of A) to D), of a lubricant or mold release agent, and D), if appropriate, further pharmaceutical excipients.
Type:
Grant
Filed:
June 2, 2008
Date of Patent:
October 29, 2013
Assignee:
BASF SE
Inventors:
Karl Kolter, Michael Schönherr, Silke Gebert, Kathrin Meyer-Böhm, Angelika Maschke
Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase or bcr-abl tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula I, in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of tuberous sclerosis associated neoplasms; to a method of treatment of warm-blooded animals, including humans, suffering from a tuberous sclerosis associated neoplasms.
Abstract: Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin; a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids; and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin; applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids; and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients.
Type:
Grant
Filed:
April 2, 2010
Date of Patent:
October 29, 2013
Assignee:
Sesvalia USA, LLC
Inventors:
Gabriel Serrano Sanmiguel, Juan Manuel Serrano Nuñez, Joaquin Melendez Zamora
Abstract: The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule.
Abstract: This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.
Abstract: A paper tissue and products made from paper tissue, such as paper handkerchiefs, facial tissues, bath and cosmetic tissues, paper tissue wipes of any kinds and the like. The invention describes both the process for making a smooth and absorbent lotioned paper tissue, with high transferability of the lotion. The process steps comprises the steps of (a) providing a paper tissue web continuously moving next to a lotion application unit comprising at least one rotating surface, (b) transferring said lotion onto one rotating surface,’(c) expulsing said lotion from the said rotating surface into a stream of lotion droplets, by primarily the centrifugal force of the rotation of said rotating surface, (d) intercepting said paper tissue with said stream of lotion droplets. The invention also describes a paper tissue comprising a lotion distributed as discrete deposits on its surface. The deposits have a high local concentration of lotion and cover a relatively small area of the tissue.
Type:
Grant
Filed:
April 14, 2005
Date of Patent:
October 15, 2013
Assignee:
The Procter & Gamble Company
Inventors:
Joerg Kleinwaechter, Dirk Butz, Curtis Allen Marcott, Luigi Di Girolamo
Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, ?,?-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4.
Type:
Grant
Filed:
May 1, 2012
Date of Patent:
October 1, 2013
Assignee:
Navidea Biopharmaceuticals, Inc.
Inventors:
Gerald Ross Magneson, Richard Cushman Orahood
Abstract: Aqueous dispersions of water-soluble and/or water-swellable anionic polymers which are obtainable by free radical polymerization of ethylenically unsaturated, anionic monomers in an aqueous medium in the presence of at leas one stabilizer, the polymerization being carried out in the presence of at least one water-soluble polymer of the groups consisting of (a) graft polymers of vinyl acetate and/or vinyl propionate on (i) polyethylene glycols or (ii) polyethylene glycols or polypropylene glycols blocked at one or both terminal groups with alkyd carboxyl or amino groups, polyalkylene glycols, polyalkylene glycols blocked at one or both terminal groups with alkyl carboxy or amino groups and (b) water-soluble copolymers of (b1) nonionic monoethylenically unsaturated monomers, (b2) cationic monoethylenically unsaturated monomers and if appropriate (b3) anionic monoethylenically unsaturated monomers, the fraction of the interpolymerized cationic monomers being greater than that of the anionic monomers, as a
Type:
Grant
Filed:
July 30, 2005
Date of Patent:
September 24, 2013
Assignee:
BASF Aktiengesellschaft
Inventors:
Volker Braig, Werner Gauweiler, Pulakesh Mukherjee, Christian Hubert Weidl
Abstract: The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicosapentaenoic acid (EPA) groups and/or docosahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions.
Type:
Grant
Filed:
March 4, 2013
Date of Patent:
September 17, 2013
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: An antimicrobial composition contains a soluble silver salt and an alkanolamine or aminoalcohol. The composition may additionally contain an amino acid or amino acid salt and surfactant. The composition has additional stability and activity compared to prior art silver complexes.
Type:
Grant
Filed:
December 5, 2008
Date of Patent:
September 17, 2013
Assignee:
The Clorox Company
Inventors:
David R. Scheuing, Erika Szekeres, Steven Bromberg
Abstract: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.
Type:
Grant
Filed:
August 19, 2011
Date of Patent:
September 17, 2013
Assignee:
Lux Biosciences, Inc.
Inventors:
Ashim K. Mitra, Poonam R. Velagaleti, Subramanian Natesan
Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
Type:
Grant
Filed:
November 12, 2010
Date of Patent:
September 17, 2013
Assignees:
Bristol-Myers Squibb Company, AstraZeneca UK Limited
Inventors:
Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
Abstract: Anhydrous antiperspirant compositions comprising particulate antiperspirant active; capsules comprising a shear-sensitive shell which encapsulates perfume; and a carrier for the particulate antiperspirant active and capsules; wherein the capsules have a shell of cross-linked gelatin coacervate having a thickness of from 0.25 to 9 ?m and providing from 10 to 40% by weight of the capsules, a volume average particle diameter of from 25 to 70 ?m, a ratio of shell thickness to the average particle diameter in the range of from 1:5 to 1:120, and a Hysitron hardness in the range of from 1.5 MPa to 50 MPa.
Type:
Grant
Filed:
October 26, 2009
Date of Patent:
August 27, 2013
Assignee:
Conopco Inc.
Inventors:
Catrin Sian Chan, Martin Peter Cropper, Kevin Ronald Franklin, Simon Anthony Johnson, Robert McKeown
Abstract: Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.
Type:
Grant
Filed:
September 27, 2011
Date of Patent:
August 27, 2013
Assignee:
University of British Columbia
Inventors:
Jayachandran N. Kizhakkedathu, Rajesh A. Shenoi, Cedric J. Carter, Donald E. Brooks
Abstract: The present invention provides solid dispersions or solid dispersion pharmaceutical preparations containing a water-soluble polymeric substance(s) and a phenylalanine compound of the formula (1) or pharmaceutically acceptable salts thereof, wherein A represents the formula (2) and the like, B represent an alkoxy group and the like, E represents a hydrogen atom and the like, D represents a substituted phenyl group and the like, T, U and V represent a carbonyl group and the like, Arm represents a benzene ring and the like, R1 represents an alkyl group and the like, R2, R3, and R4 may be the same or different from one another and each represent a hydrogen atom, a substituted amino group and the like, and J and J? represent a hydrogen atom and the like; production methods thereof; and solubilized pharmaceutical preparations containing a solubilizer(s) and the compound (I) or pharmaceutically acceptable salts thereof.